# Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer

> **NCT00222469** · PHASE2 · COMPLETED · sponsor: **University of Oklahoma** · enrollment: 50 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** gemcitabine
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00222469
- **Lead sponsor:** University of Oklahoma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2008-07-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00222469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00222469, "Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00222469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*